Multiplex Brain Proteomic Analysis Revealed the Molecular Therapeutic Effects of Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Oct 23

PMID 26492191

Citations 20

Authors

Hong-Jhang Chen

Yuh-Chiang Shen

Young-Ji Shiao

Kuo-Tong Liou

Wei-Hsiang Hsu

Pei-Hsuan Hsieh

Chi-Ying Lee

Yet-Ran Chen

Yun-Lian Lin

Affiliations

Soon will be listed here.

Abstract

Stroke is the second-leading cause of death worldwide, and tissue plasminogen activator (TPA) is the only drug used for a limited group of stroke patients in the acute phase. Buyang Huanwu Decoction (BHD), a traditional Chinese medicine prescription, has long been used for improving neurological functional recovery in stroke. In this study, we characterized the therapeutic effect of TPA and BHD in a cerebral ischemia/reperfusion (CIR) injury mouse model using multiplex proteomics approach. After the iTRAQ-based proteomics analysis, 1310 proteins were identified from the mouse brain with <1% false discovery rate. Among them, 877 quantitative proteins, 10.26% (90/877), 1.71% (15/877), and 2.62% (23/877) of the proteins was significantly changed in the CIR, BHD treatment, and TPA treatment, respectively. Functional categorization analysis showed that BHD treatment preserved the integrity of the blood-brain barrier (BBB) (Alb, Fga, and Trf), suppressed excitotoxicity (Grm5, Gnai, and Gdi), and enhanced energy metabolism (Bdh), thereby revealing its multiple effects on ischemic stroke mice. Moreover, the neurogenesis marker doublecortin was upregulated, and the activity of glycogen synthase kinase 3 (GSK-3) and Tau was inhibited, which represented the neuroprotective effects. However, TPA treatment deteriorated BBB breakdown. This study highlights the potential of BHD in clinical applications for ischemic stroke.

Citing Articles

Proteomic advance of ischemic stroke: preclinical, clinical, and intervention.

Zhao T, Zeng J, Zhang R, Pu L, Wang H, Pan L Metab Brain Dis. 2023; 38(8):2521-2546.

PMID: 37440002 DOI: 10.1007/s11011-023-01262-y.

What can traditional Chinese medicine do for adult neurogenesis?.

Shen W, Jiang N, Zhou W Front Neurosci. 2023; 17:1158228.

PMID: 37123359 PMC: 10130459. DOI: 10.3389/fnins.2023.1158228.

A New Therapeutic Trend: Natural Medicine for Ameliorating Ischemic Stroke via PI3K/Akt Signaling Pathway.

Liu X, Xiao X, Han X, Yao L, Lan W Molecules. 2022; 27(22).

PMID: 36432062 PMC: 9694461. DOI: 10.3390/molecules27227963.

Buyang Huanwu Tang protects HO-induced RGC-5 cell against oxidative stress and apoptosis reactive oxygen species-mitogen-activated protein kinase signaling pathway.

Wei Z, Mingxing W, Shanxue L, Chao L, Yanqiu Z, Duoduo X J Tradit Chin Med. 2022; 42(6):885-891.

PMID: 36378045 PMC: 9924709. DOI: 10.19852/j.cnki.jtcm.2022.06.004.

Lithium Biological Action Mechanisms after Ischemic Stroke.

Munteanu C, Rotariu M, Turnea M, Tataranu L, Dogaru G, Popescu C Life (Basel). 2022; 12(11).

PMID: 36362835 PMC: 9697783. DOI: 10.3390/life12111680.

References

Fan L, Wang K, Cheng B . Effects of buyang huanwu decoction on apoptosis of nervous cells and expressions of Bcl-2 and bax in the spinal cord of ischemia-reperfusion injury in rabbits. J Tradit Chin Med. 2006; 26(2):153-6. View

Prajapati K, Sharma S, Roy N . Upregulation of albumin expression in focal ischemic rat brain. Brain Res. 2010; 1327:118-24. DOI: 10.1016/j.brainres.2010.02.063. View

Chen C, Tseng M, Lin H, Lin T, Chen Y . Visual indicator for surfactant abundance in MS-based membrane and general proteomics applications. Anal Chem. 2010; 82(19):8283-90. DOI: 10.1021/ac1017937. View

Imhof A, Charnay Y, Vallet P, Aronow B, Kovari E, French L . Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol Dis. 2006; 22(2):274-83. DOI: 10.1016/j.nbd.2005.11.009. View

Altamura C, Squitti R, Pasqualetti P, Gaudino C, Palazzo P, Tibuzzi F . Ceruloplasmin/Transferrin system is related to clinical status in acute stroke. Stroke. 2009; 40(4):1282-8. DOI: 10.1161/STROKEAHA.108.536714. View

Keller A, Nesvizhskii A, Kolker E, Aebersold R . Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002; 74(20):5383-92. DOI: 10.1021/ac025747h. View

Lansberg M, Bluhmki E, Thijs V . Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009; 40(7):2438-41. PMC: 2725521. DOI: 10.1161/STROKEAHA.109.552547. View

Ulrich-Merzenich G, Zeitler H, Jobst D, Panek D, Vetter H, Wagner H . Application of the "-Omic-" technologies in phytomedicine. Phytomedicine. 2006; 14(1):70-82. DOI: 10.1016/j.phymed.2006.11.011. View

Guo W, Murthy A, Zhang L, Johnson E, Schaller E, Allan A . Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet. 2011; 21(3):681-91. PMC: 3259018. DOI: 10.1093/hmg/ddr501. View

10.

Cohen P, Frame S . The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-76. DOI: 10.1038/35096075. View

11.

DeSouza L, Diehl G, Rodrigues M, Guo J, Romaschin A, Colgan T . Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2005; 4(2):377-86. DOI: 10.1021/pr049821j. View

12.

Niswender C, Conn P . Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010; 50:295-322. PMC: 2904507. DOI: 10.1146/annurev.pharmtox.011008.145533. View

13.

Zheng G, Wang X, Wang Y, Wang X . Tau as a potential novel therapeutic target in ischemic stroke. J Cell Biochem. 2009; 109(1):26-9. DOI: 10.1002/jcb.22408. View

14.

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

15.

Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G . Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosci. 2003; 23(5):1949-55. PMC: 6741971. View

16.

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

17.

Bao W, Williams A, Faden A, Tortella F . Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res. 2001; 922(2):173-9. DOI: 10.1016/s0006-8993(01)03062-1. View

18.

Tan Z, Turner R, Leon R, Li X, Hongpaisan J, Zheng W . Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Stroke. 2013; 44(12):3490-7. PMC: 4041549. DOI: 10.1161/STROKEAHA.113.002411. View

19.

Lo E, Dalkara T, Moskowitz M . Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003; 4(5):399-415. DOI: 10.1038/nrn1106. View

20.

Cho W . Application of proteomics in Chinese medicine research. Am J Chin Med. 2008; 35(6):911-22. DOI: 10.1142/S0192415X07005375. View